Loading…
← CockpitCompetitor Analysis › BLTE Belite Bio, Inc. ADROpen in the cockpit ↗

Belite Bio, Inc. ADRBLTECompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing tinlarebant, an oral drug to slow vision loss in inherited and age-related retinal diseases.

Momentum strong 63
Mkt cap
$6.41B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$26.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-27.5 pp
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
128 days
26 Mar 2027
Close · USD$156.23
1D-0.9%
1W+0.2%
1M+1.1%
3M-3.5%
6M+9.0%
YTD-2.3%
1Y+33.6%
ATR %5.0%
Beta1.04
52w lowhigh21.9% off high

What Belite Bio, Inc. ADR does

Clinical-stage biotech developing tinlarebant, an oral drug to slow vision loss in inherited and age-related retinal diseases.

Has no product to sell, so its costs are paid from investor money raised in share sales. Its value hinges on late-stage trial results for tinlarebant and on regulatory approvals.

Products and services

  • Tinlarebant (Stargardt disease/geographic atrophy, pipeline)

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Ophthalmology - retinal disease

What could go right

  • First approved oral therapy for Stargardt disease
  • Large unmet need in geographic atrophy

What could go wrong

  • Pre-revenue clinical/regulatory risk
  • Small company scale vs larger ophthalmology rivals

Moat: none (IP / patents). Pre-commercial; edge rests on being an oral alternative to injectable treatments for retinal disease.

Headquarters: San Diego, California, United States · Founded: 2018 · Employees: 41

Named competitors

Belite Bio, Inc. ADR at a glance

Size Belite Bio, Inc. ADR (BLTE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $6.41B, the 1009th largest of 3,085 United States companies the cockpit tracks. Shares closed at $156.23 on 18 Nov 2026.

Performance Over six months the shares gained 9.0%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.

Capital Return on invested capital runs 27.5 points below its cost of capital (6.6% WACC).

Short interest Short interest is 3.4% of the free float (30 Oct 2026).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026BLTE 108Peer median 93
Six months, rebased to 100: Belite Bio, Inc. ADR against the median of its 20 peers (local-currency closes).

Belite Bio, Inc. ADR financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit$0-$464,000-$449,000-$399,000-$198,000
EBITDAn/a-$83.7M-$39.5M-$31.3M-$12.6M
Net income-$111M-$77.6M-$36.1M-$31.6M-$12.6M
Free cash flown/a-$37.1M-$29.4M-$29.9M-$11.9M
Capital expendituren/a$71,000$151,000$63,000$394,000
Total debtn/a$429,000$537,000$886,000$866,000

Quarterly statements and history in the cockpit →

Belite Bio, Inc. ADR competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%0126Z0ORKABIOCON688331000999ALKEM000963MIRMSUPNLGND9926BANB6821IBRXCYTKGLAND603087BLTE6-month return →1-month return →
Up and to the right = strong over both horizons. Belite Bio, Inc. ADR is the large dot.

Belite Bio, Inc. ADR competitors and peer comparison

Head to head with its named competitors (BLTE vs IONS vs 4503.T vs ANNX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Belite Bio, Inc. ADR BLTE$6.41B+9%n/an/an/an/a
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%5.0×n/a
Astellas Pharma 4503.T$31.4B+17%+19%23%2.2×-9.0%
Annexon ANNX$671M-30%n/an/an/an/a
Ocugen OCGNn/a-46%n/an/an/an/a

How Belite Bio, Inc. ADR compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Belite Bio, Inc. ADR against its 20 peers (data as of 18 Nov 2026)
MeasureBLTEPeer medianRank in peer set
1-month return+1.1%-2.1%10th highest of 21
6-month return+9.0%-4.6%6th highest of 20
Distance from 52-week high-21.9%-20.4%10th lowest of 21
ROIC minus cost of capital-27.5 pp+2.2 pp3rd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%5.9×n/an/a
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Biocon BIOCON.NSIndia$6.31B-15%+6%8%4.3×n/an/a
RemeGen 688331.SSChina$6.28B-24%+272%61%4.4×1.1%+303.3%
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%3.5×-11.9%+4.2%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%1.9×-6.2%+18.4%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%4.1×25.0%+10.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%1.1×-3.9%+5.3%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%9.6×n/an/a
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%4.5×6.2%+13.9%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%26.3×57.7%+7.5%
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%12.9×n/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%8.6×n/an/a
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%7.3×8.0%+10.0%
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%5.8×n/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%44.3×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%64.3×n/an/a
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%7.1×20.2%+13.3%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%2.1×-6.8%+10.8%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%7.6×n/an/a

Questions

Who are Belite Bio, Inc. ADR's main competitors?
Named competitors: Ionis Pharmaceuticals (IONS), Alkeus Pharmaceuticals (private or unlisted), Apellis Pharmaceuticals (private or unlisted), Astellas Pharma (4503.T), Annexon (ANNX), Ocugen (OCGN). The cockpit's measured peer set (industry) also includes Samsung Epis (0126Z0.KS), Oruka Therapeutics (ORKA), Biocon (BIOCON.NS), RemeGen (688331.SS), Apotex Health (APTX.TO), China Resources Sanjiu Medical & Pharmaceutical (000999.SZ).
How has Belite Bio, Inc. ADR stock performed?
Over six months to 18 Nov 2026 the shares returned +9.0% against -4.6% for the median peer; over one year +33.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.